Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Upon completion of this ASR, Collegium will have $100 million remaining under the program.

GlobeNewsWire • Aug 13, 2026

Collegium Pharmaceutical Q2 Earnings Call Highlights

Collegium Pharmaceutical NASDAQ: COLL reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower revenue from the NUCYNTA pain franchise.

MarketBeat • Aug 6, 2026

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

– Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $46.1 Million, Up 41% Year-over-Year – – Generated AZSTARYS Quarterly Net Revenue of $12.9 Million, Representing a Partial Quarter of Sales – – Generated Quarterly Pain Portfolio Net Revenues of $140.9 Million – – Updates Full-Year 2026 Financial Guidance – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.

GlobeNewsWire • Aug 6, 2026

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Aug 6, 2026

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.68 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, leveraging stable pain cash flows to fuel ADHD franchise growth. The AZSTARYS acquisition, funded with $350M cash and $300M debt, is expected to deliver $60–70M revenue in 2026 and $50M+ annual synergies within 12 months. COLL's 2026 guidance is $865–895M in revenue and $475–500M adjusted EBITDA, with a 55% margin, reflecting only partial-year AZSTARYS contribution and early synergies.

Seeking Alpha • Aug 1, 2026

Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026

STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report second quarter 2026 financial results before the market opens on Thursday August 6, 2026.

GlobeNewsWire • Jul 23, 2026

Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston

STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced plans to relocate its corporate headquarters to One Lincoln in downtown Boston in the first quarter of 2027.

GlobeNewsWire • Jul 20, 2026

DivcoWest Welcomes Collegium Pharmaceutical to One Lincoln

BOSTON--(BUSINESS WIRE)--DivcoWest, a DivCore Capital company and national commercial real estate investment firm, today announced that Collegium Pharmaceutical, a leading biopharmaceutical company, has signed a lease for 40,288 square feet on floors 11 and 12 at One Lincoln in Boston's Financial District. The 36‑story, 1.1‑million‑square‑foot Class A office tower completed a transformative renewal in 2025 and now serves as a landmark next-generation workplace for world-class established and gr.

Business Wire • Jul 20, 2026